Scripps 36th Annual New Treatments in Chronic Liver Disease 2022 (Course)
50 $
Format : 17 MP4 + 1 PDF files
File Size : 4.92 GB
This conference covers the latest medications and therapies in liver treatment and transplantation, including chronic viral hepatitis, non-alcoholic fatty liver diseases, primary biliary cirrhosis, hepatocellular carcinoma, and complications of end-stage liver disease. Educational objectives include assessing guidelines and summarizing advances in liver disease treatment. The target audience is hepatologists, gastroenterologists, and infectious disease specialists. Topics include DILI, HCC, NAFLD, autoimmune hepatitis, non-invasive testing, reproductive health, management of ascites and HRS, viral hepatitis B and C, vascular disorders, anticoagulation, and liver transplantation.
Scripps 36th Annual New Treatments in Chronic Liver Disease 2022 (Course)
The Scripps 36th annual New Treatments in Chronic Liver Disease conference is dedicated to reviewing the recent medications and therapies in the treatment of liver disease and transplantation. This extensive program will explore the findings of experiments and real-world data regarding the efficacy of oral drugs in treating chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma, and complications associated with end-stage liver disease, including thrombocytopenia. This training program aims to provide doctors with the most recent information on the commonly encountered issues in the treatment of liver diseases in a concise yet comprehensive manner.
Educational Goals:
AASLD Guidelines and Chronic Liver Disease: participants will evaluate the guidelines established by the American Association for the Study of Liver Diseases (AASLD) regarding viral hepatitis, autoimmune hepatitis, and reproductive health, as well as chronic liver disease. This understanding will help to direct clinical decisions and improve the care of patients.
Vascular Disorders and Coagulation Management: The conference will discuss the common diagnoses of vascular disease that are associated with chronic liver disease, and provide principles for dealing with this condition.
Guidelines and Non-Invasive Markers: participants will discuss the guidelines established by organizations like the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), and the European Association for the Study of the Liver (EASL) regarding non-alcoholic fatty liver disease (NAFLD), drug-induced liver damage (DILI), hemochromatosis, and non-invasive markers of fibrosis. This will facilitate the optimization of diagnosis and treatment options.
Advances in PBC, PSC, and HCC: The training will provide information on upcoming drugs for the treatment of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), as well as discuss advances in the treatment of hepatocellular carcinoma (HCC). participants will learn about the latest treatment options and strategies for dealing with these disorders.
ascites, hepatorenal syndrome, and acute-on-chronic liver disease: Strategies for dealing with and treating these conditions will be described, providing participants with the necessary tools to address these issues effectively.
Target audience:
The training is intended for a variety of healthcare professionals that specialize in liver disease, including:
Hepatologists
Gastroenterologists
Infection Disease Experts
By attending the Scripps 36th annual New Treatments in Chronic Liver Disease conference, participants will learn about the latest developments in the field, will have a comprehensive understanding of the available options, and will increase their capacity to provide the best care to patients with chronic liver diseases.
Topics:
ACG Guidelines for DILI and Hemochromatosis – Kris Kowdley, MD
Acute-on-Chronic Liver Disease – Timothy Morgan, MD
Advanced Endoscopy in Liver Disease Patients – Matthew Skinner, MD
Advances in HCC – Catherine Frenette, MD
AGA Guidelines for NAFLD – Mazen Noureddin, MD
Autoimmune Hepatitis – John Vierling, MD
Debate- Use of Semaglutide for Obese Patients with NAFLD – Paul J. Pockros, MD, Michael Charlton, MD
EASL Guidelines for Non-Invasive Testing – Michael Charlton, MD
Panel Discussion1
Panel Discussion2
Panel Discussion3
Reproductive Health and Chronic Liver Disease – Norah Terrault, MD
Update on Management of Ascites and HRS – Florence Wong, MD
Vascular Disorders and Anticoagulation – Patrick Northup, MD
Viral Hepatitis B and C – Julio Gutierrez, MD
When to Refer for Liver Transplantation – Adam Deising, MD
WILLIAM S. HAUBRICH LECTURE- What’s New in PBC and PSC- – Kris Kowdley, MD
Related Products
